Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) Equity Average (2019 - 2026)

Atea Pharmaceuticals' Equity Average history spans 8 years, with the latest figure at $254.6 million for Q1 2026.

  • Quarterly Equity Average fell 40.1% to $254.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $254.6 million through Mar 2026, down 40.1% year-over-year, with the annual reading at $357.2 million for FY2025, 28.14% down from the prior year.
  • Equity Average came in at $254.6 million for Q1 2026, down from $295.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $695.0 million in Q1 2022 to a low of $254.6 million in Q1 2026.
  • The 5-year median for Equity Average is $529.8 million (2024), against an average of $512.8 million.
  • Year-over-year, Equity Average grew 22.57% in 2022 and then crashed 40.1% in 2026.
  • Atea Pharmaceuticals' Equity Average stood at $651.9 million in 2022, then dropped by 12.8% to $568.5 million in 2023, then fell by 21.07% to $448.7 million in 2024, then crashed by 34.12% to $295.6 million in 2025, then decreased by 13.88% to $254.6 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Equity Average are $254.6 million (Q1 2026), $295.6 million (Q4 2025), and $340.1 million (Q3 2025).